<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022654</url>
  </required_header>
  <id_info>
    <org_study_id>SI-B001_207</org_study_id>
    <nct_id>NCT05022654</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma.</brief_title>
  <official_title>Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of si-B001 monotherapy RP2D and single-dose low-dose combined with&#xD;
      irinotecan in patients with locally advanced or metastatic esophageal squamous cell carcinoma&#xD;
      (ESCC) obtained in phase I clinical trials.&#xD;
&#xD;
      To evaluate the safety and tolerability of si-B001 monotherapy RP2D and single-dose low-dose&#xD;
      combined with irinotecan in patients with locally advanced or metastatic esophageal squamous&#xD;
      cell carcinoma (ESCC) obtained in phase I clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Disease-control rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Squamous Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>Cohort_A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recurrent and metastatic esophageal squamous cell carcinoma who failed pD-1 (L1) -containing mab in the first line were treated with SI-B001 in combination with irinotecan in the second line.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort_B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recurrent and metastatic ESOPHAGEAL squamous cell carcinoma who failed pD-1 (L1) -containing mab in the second line were treated with SI-B001 combined with irinotecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI-B001</intervention_name>
    <description>Administration by intravenous infusion</description>
    <arm_group_label>Cohort_A</arm_group_label>
    <arm_group_label>Cohort_B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age: ≥18 years and ≤75 years;&#xD;
&#xD;
          2. Expected survival time ≥3 months;&#xD;
&#xD;
          3. Locally advanced esophageal squamous cell carcinoma confirmed histologically or&#xD;
             pathologically as recurrent or metastatic or without indications of radical local&#xD;
             treatment;&#xD;
&#xD;
          4. Patients who had failed or were intolerant to prior anti-PD-1 (L1) mab or mab&#xD;
             containing anti-PD-1 (L1) mab combined with chemotherapy.&#xD;
&#xD;
          5. Previously only received ≤2 line therapy for recurrent and metastatic esophageal&#xD;
             squamous cell carcinoma;&#xD;
&#xD;
          6. Agree to provide archived tumor tissue specimens of primary or metastatic lesion (4&#xD;
             surgical specimens (thickness 5μm) without staining section (anti-removal);6 unstained&#xD;
             sections (anti-removal) surgical specimens (thickness 10μm) or fresh tissue samples,&#xD;
             if the patient cannot provide, can be included after the investigator's judgment;&#xD;
&#xD;
          7. There must be at least one measurable lesion conforming to the RECIST V1.1 definition.&#xD;
             Tumor lesion located in the area of previous radiotherapy or other local and regional&#xD;
             treatment sites is generally not a measurable lesion unless there is definite&#xD;
             progression of the lesion or the lesion persists three months after radiotherapy;&#xD;
&#xD;
          8. Physical fitness ECOG score of 0 or 1;&#xD;
&#xD;
          9. Toxicity from previous antitumor therapy has returned to ≤1 as defined by NCI-CTCAE&#xD;
             V5.0 (except for toxicity that the investigators determined to be of no safety risk,&#xD;
             such as hair loss, grade 2 peripheral neurotoxicity, and stabilized hypothyroidism&#xD;
             after hormone replacement therapy);&#xD;
&#xD;
         10. Organ function levels must meet the following requirements and meet the following&#xD;
             standards:&#xD;
&#xD;
             A) Bone marrow function: absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count&#xD;
             ≥90×10^9/L, hemoglobin ≥90 g/L; B) Liver function: Total bilirubin TBIL≤1.5×ULN (total&#xD;
             bilirubin ≤3×ULN in Subjects with Gilbert's syndrome, liver cancer or liver&#xD;
             metastasis), AST and ALT ≤2.5×ULN in patients without liver metastasis, AST and ALT&#xD;
             ≤5.0×ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr)&#xD;
             ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to Cockcroft and Gault&#xD;
             formula); D) Urine routine / 24-hour protein quantification: qualitative urine protein&#xD;
             ≤1+ (if qualitative urine protein ≥2+, 24 hours &lt; 1g can be included); E) Cardiac&#xD;
             function: left ventricular ejection fraction ≥50%; F) Coagulation function:&#xD;
             International standardized ratio (INR) ≤1.5×ULN, and activated partial thrombin time&#xD;
             (APTT) ≤1.5×ULN;&#xD;
&#xD;
         11. Eligible patients (male and female) who are fertile must agree to use a reliable&#xD;
             contraceptive method (hormonal or barrier method or abstinence, etc.) with their&#xD;
             partner during the trial and for at least 6 months after the last medication;Women of&#xD;
             childbearing age must have a negative blood or urine pregnancy test within 7 days&#xD;
             prior to the first use of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy&#xD;
             and other anti-tumor therapy within 4 weeks prior to the first use of the study drug,&#xD;
             except for the following:&#xD;
&#xD;
             Oral fluorouracil and small molecule targeted drugs were used within 2 weeks before&#xD;
             the first administration of the study drug or within 5 half-lives of the drug; The&#xD;
             traditional Chinese medicines with anti-tumor indications were within 2 weeks before&#xD;
             the first use of the study drug;&#xD;
&#xD;
          2. Patients with esophageal fistula;&#xD;
&#xD;
          3. Received an unmarketed clinical investigational drug or treatment within 4 weeks prior&#xD;
             to initial use of the investigational drug;&#xD;
&#xD;
          4. Had major organ surgery (excluding needle biopsy, tracheotomy, gastrostomy, etc.) or&#xD;
             had significant trauma within 4 weeks prior to the first use of study drugs, or needed&#xD;
             to undergo elective surgery during the trial;&#xD;
&#xD;
          5. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation;&#xD;
&#xD;
          6. A history of serious cardiovascular and cerebrovascular diseases, including but not&#xD;
             limited to:&#xD;
&#xD;
             Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias&#xD;
             requiring clinical intervention, grade iii atrioventricular block, etc； In the resting&#xD;
             state, QT interval was prolonged (QTc &gt; 450 msec in men or QTc &gt; 470 msec in women)；&#xD;
             Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other&#xD;
             grade 3 or higher cardio-cerebrovascular events within 6 months prior to the first&#xD;
             administration; New York Heart Association (NYHA) heart function grade ≥II heart&#xD;
             failure;&#xD;
&#xD;
          7. Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus,&#xD;
             inflammatory bowel disease, etc., except type I diabetes, hypothyroidism that can be&#xD;
             controlled only with replacement therapy, and skin diseases that do not require&#xD;
             systemic treatment;&#xD;
&#xD;
          8. Patients with a history of other malignant tumors and signs of recurrence and&#xD;
             metastasis within 1 year before the first administration;&#xD;
&#xD;
          9. Poorly controlled hypertension (systolic blood pressure &amp; GT;150 mmHg or diastolic&#xD;
             pressure &amp;gt;100 mmHg);&#xD;
&#xD;
         10. Pulmonary disease of grade 3 or higher defined by CTCAE V5.0;Patients with past or&#xD;
             present interstitial lung disease (ILD);&#xD;
&#xD;
         11. Cerebral parenchymal or meningeal metastases with clinical symptoms were not suitable&#xD;
             for inclusion.&#xD;
&#xD;
         12. Previous use of anti-EGFR antibody drug therapy;&#xD;
&#xD;
         13. There are known allergic contraindications to any excipients of SI-B001 or irinotecan;&#xD;
&#xD;
         14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active&#xD;
             hepatitis B virus infection or hepatitis C virus infection;&#xD;
&#xD;
         15. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia,&#xD;
             septicemia, etc；'&#xD;
&#xD;
         16. Pregnant or lactating women;&#xD;
&#xD;
         17. Persons with mental disorders or poor compliance;&#xD;
&#xD;
         18. The investigator considers that the subject has a history of other serious systemic&#xD;
             diseases or other reasons to be unsuitable for this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+8613980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao</last_name>
    <phone>+8615013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

